Evidence map›Paper›PMID 32157151›Full record

ArticleScientific reports2020

Ensemble modeling highlights importance of understanding parasite-host behavior in preclinical antimalarial drug development.

Lydia Burgert, Matthias Rottmann, Sergio Wittlin, Nathalie Gobeau, Andreas Krause, Jasper Dingemanse, Jörg J Möhrle, Melissa A Penny

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
1.8field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 14 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Article
  6. Parasite Viability as a Measure ofAntimicrobial agents and chemotherapy · 2022
    Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Lydia BurgertSwiss Tropical and Public Health Institute, Basel, Switzerland.
Matthias RottmannSwiss Tropical and Public Health Institute, Basel, Switzerland.
Sergio WittlinSwiss Tropical and Public Health Institute, Basel, Switzerland.
Nathalie GobeauMedicines for Malaria Venture, Geneva, Switzerland.
Andreas KrauseIdorsia Pharmaceuticals Ltd, Clinical Pharmacology, Allschwil, Switzerland.
Jasper DingemanseIdorsia Pharmaceuticals Ltd, Clinical Pharmacology, Allschwil, Switzerland.
Jörg J MöhrleSwiss Tropical and Public Health Institute, Basel, Switzerland.
Melissa A PennySwiss Tropical and Public Health Institute, Basel, Switzerland. melissa.penny@unibas.ch.ORCID 0000-0002-4972-593X
Swiss Tropical and Public Health Institute · CHIdorsia (Switzerland) · CHMedicines for Malaria Venture · CH

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Emerging drug resistance and high-attrition rates in early and late stage drug development necessitate accelerated development of antimalarial compounds. However, systematic and meaningful translation of drug efficacy and host-parasite dynamics between preclinical testing stages is missing. We developed an ensemble of mathematical within-host parasite growth and antimalarial action models, fitted to extensive data from four antimalarials with different modes of action, to assess host-parasite interactions in two preclinical drug testing systems of murine parasite P. berghei in mice, and human parasite P. falciparum in immune-deficient mice. We find properties of the host-parasite system, namely resource availability, parasite maturation and virulence, drive P. berghei dynamics and drug efficacy, whereas experimental constraints primarily influence P. falciparum infection and drug efficacy. Furthermore, uninvestigated parasite behavior such as dormancy influences parasite recrudescence following non-curative treatment and requires further investigation. Taken together, host-parasite interactions should be considered for meaningful translation of pharmacodynamic properties between murine systems and for predicting human efficacious treatment.

Indexed as

AnimalsAntiprotozoal AgentsDisease Models, AnimalDrug DevelopmentDrug ResistanceHost-Parasite InteractionsHumansMalaria, FalciparumMiceMice, SCIDModels, TheoreticalPlasmodium bergheiPlasmodium falciparumAntiprotozoal Agents

Identifiers

PMID32157151
PMCPMC7064600
OpenAlexW3012019562

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.